News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
Fujifilm India recently introduced a “Covid-19 Pneumonia Image Analysis Program” that helps in diagnosing chest CT images that helps in findings of Covid-19 pneumonia
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Second interchangeable biosimilar product approved by agency
Equity raise to finance growth and investments in the biological space
The company plans to raise US $ 15 million
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Subscribe To Our Newsletter & Stay Updated
